Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Hoffmann-La Roche
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 4 ans
A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients with Mild to Moderate Asthma
•To evaluate the efficacy of lebrikizumab compared with placebo in improving lung function, as measured by the absolute change in pre-bronchodilator forced expiratory volume in 1 second (FEV1), in adu...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 4 ans
A multicentre, open-label, randomized, phase III study to evaluate the efficacy of Tarceva™ or comparator Alimta® (pemetrexed) or Taxotere® (docetaxel) in patients with histologically documented, advanced or recurrent (stage IIIB and not amenable for combined modality treatment) or metastatic (Stage IV) non-small cell lung cancer who have experienced disease progression during platinum-based chemotherapy
To determine if the administration of Tarceva™ after disease progression on standard platinum-based chemotherapy in the treatment of NSCLC results in improved overall survival when compared to Alimta®...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Hoffmann-La Roche
Update Il y a 4 ans
Étude WO39391 : étude de phase 3 randomisée comparant l’efficacité de l’atézolizumab associé à une chimiothérapie de type T-AC (Taxotère®, adriamycine et cyclophosphamide) avec celle de la chimiothérapie de type T-AC seule chez des patients ayant un cancer du sein triple négatif (HER2, ER et PgR).
De nombreuses cellules du cancer du sein ont des récepteurs d’oestrogènes ou de progestérone. Elles peuvent aussi avoir des récepteurs pour une protéine appelée HER2, ou ErbB2. Le cancer du sein tripl...
Country
France
organs
Sein
Specialty
Chimiothérapie
,
Immunothérapie - Vaccinothérapie
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 4 ans
A Phase III, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study, Evaluating the Safety, Tolerability and Efficacy of RO4607381 by Measuring Flow Mediated Dilatation in the Brachial Artery, 24 hour Ambulatory Blood Pressure, Lipids, Lipoproteins and Markers Vascular Inflammation, Oxidation and CV risk in Patients with Coronary Heart Disease (CHD) or CHD Risk Equivalents
The primary efficacy objective of this study is to evaluate the effect of RO4607381 on endothelial function as measured by flow mediated dilatation (FMD) of the brachial artery in patients with CHD or...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 4 ans
An open-label, randomized, multicenter, parallel group study to demonstrate correction of anemia using intravenous injections of RO0503821 in patients with chronic kidney disease who are on dialysis
To demonstrate the efficay of IV RO 0503821
Country
None
organs
None
Specialty
None
unknown
More information
Woman
Between 18 years
and 99 years
Hoffmann-La Roche
Update Il y a 5 ans
Étude Imagyn050 : étude de phase 3 randomisée comparant l’efficacité de l’atézolizumab en association avec du paclitaxel, du carboplatine et du bévacizumab avec celle d’un placebo en association avec du paclitaxel, du carboplatine et du bévacizumab chez des patients ayant un cancer de l’ovaire, de la trompe de Fallope ou du péritoine nouvellement diagnostiqué de stade III ou IV. [Informations issues du site clinicaltrials.gov et traduites par l'INCa]
Le cancer de l’ovaire est un cancer rare, qui touche les femmes le plus souvent autour de 65 ans. Il en existe plusieurs types, selon le type de cellules où la tumeur prend naissance. Les cellules d’...
Country
France
organs
Ovaire
,
Appareil génital féminin - autres
,
Péritoine
Specialty
Immunothérapie - Vaccinothérapie
,
Chimiothérapie
Essai ouvert aux inclusions
More information
Woman and Man
Between 18 years
and 99 years
Hoffmann-La Roche
Update Il y a 4 ans
Étude MODUL : étude de phase 2, randomisée, évaluant l’efficacité et la tolérance d’un traitement de maintenance guidé par biomarqueur, chez des patients ayant un cancer colorectal métastatique. [essai suspendu] [essai clos aux inclusions]
A Multi-centre Randomised Clinical Trial of Biomarker-driven Maintenance Treatment for First-line Metastatic Colorectal Cancer (MODUL)
Country
France
organs
Côlon ou Rectum (colorectal)
Specialty
Chimiothérapie
,
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Roche Farma, S.A., que representa en España a F. Hoffmann-La Roche Ltd
Update Il y a 4 ans
A Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Emicizumab in Hemophilia A Pediatric Patients With Inhibitors Estudio Fase III para evaluar la Eficacia, Seguridad y Farmacocinética de Emicizumab en pacientes pediatricos con hemofilia A con inhibidores
There is no formal hypothesis testing in the study. Efficacy ? To evaluate clinical effect of prophylactic emicizumab on number of bleeds over time (bleed rate) ? To characterize efficacy of up-titrat...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 4 ans
A phase II marker identification trial for Tarceva in second line NSCLC patients
The primary objective is the identification of differentially expressed genes that are predictive for benefit of Tarceva treatment.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 4 ans
Estudio multicéntrico, abierto, de dosis múltiples, para determinar la dosis inicial óptima de MIRCERA® administrada por vía intravenosa para el tratamiento de mantenimiento de la anemia en pacientes pediátricos con enfermedad renal crónica en Hemodiálisis
– Determinar la dosis inicial de MIRCERA® en pacientes pediátricos con ERC en hemodiálisis, que hayan sido tratados previamente durante una fase de mantenimiento de manera estable con epoetina alfa, e...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
4
5
6
7
8
9
10
Next